Astrazeneca Ab

Marianne Bernice Ashford

William McCoull

John Paul Secrist

Iain Grant

Michael Giannis

Brian Kelly

Edward John Hennessy

David Owen

Greg Troiano

Young-Ho Song

Hong Wang

Eyoung Shin

James Martin Nolan, Iii

Francis Thomas Boyle

David William Tonge

Andrew Mark Hughes

Donna Johnstone

Nigel Charles Barrass

Sian Tomiko Taylor

Iii Nolan James Martin

James Martin Iii Nolan

Disclosed are dendrimers of formula (I): and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.

Therapeutic dendrimers

Described herein are polymeric nanoparticles that include a therapeutic agent which is 2-(3-((7-(3-(ethyl(2-hydroxyethyl)amino)propoxy)quinazolin-4-yl)amino)-1H-pyrazol-5-yl)-N-(3-fluorophenyl)acetamide (also known as AZD1152 hqpa) or a pharmaceutically acceptable salt thereof, and methods of making and using such therapeutic nanoparticles.

Therapeutic polymeric nanoparticles and methods of making and using same

The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.

N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl-phenyl)pyridine-3 sulphonamide as an anticancer agent

Growing community of inventors

Macclesfield, United Kingdom

Marianne Bernice Ashford